Skip to content

Study · Randomized controlled trial · 2011

3 results

Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial.

Steward RG, Gill I, Williams DB, Witz CA, Griffith J, Haddad GF

Fertility and sterility1 Jan 2011Cited by 13 (Europe PMC)

PMID20810107 (opens in a new tab)DOI10.1016/j.fertnstert.2010.07.1076 (opens in a new tab)PepBankPUB-20810107
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In OI-IUI cycles, cetrorelix significantly reduced premature luteinization compared with the protocol without cetrorelix.

    In plain wordsIn OI-IUI cycles, cetrorelix reduced premature luteinization compared with the protocol without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature luteinization
    Study

    n: not reported in source

    Comparator
    OI-IUI protocol without cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those in the cetrorelix arm showed a significantly reduced rate of PL and no change in clinical pregnancy or cycle cancellation rate,
    1 context sentence
    Summary · context
    Attempting to compare the rates of premature luteinization (PL), clinical pregnancy, and cycle cancellation in ovulation induction-intrauterine insemination (OI-IUI) cycles with and without the GnRH antagonist, cetrorelix, a randomized-controlled trial was undertaken in which patients were randomize…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In OI-IUI cycles, cetrorelix did not change clinical pregnancy rates compared with the protocol without cetrorelix.

    In plain wordsIn OI-IUI cycles, cetrorelix did not change pregnancy rates compared with the protocol without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy
    Study

    n: not reported in source

    Comparator
    OI-IUI protocol without cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those in the cetrorelix arm showed a significantly reduced rate of PL and no change in clinical pregnancy or cycle cancellation rate,
    1 context sentence
    Summary · context
    Attempting to compare the rates of premature luteinization (PL), clinical pregnancy, and cycle cancellation in ovulation induction-intrauterine insemination (OI-IUI) cycles with and without the GnRH antagonist, cetrorelix, a randomized-controlled trial was undertaken in which patients were randomize…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In OI-IUI cycles, cetrorelix did not change cycle cancellation rates compared with the protocol without cetrorelix.

    In plain wordsIn OI-IUI cycles, cetrorelix did not change cycle cancellation rates compared with the protocol without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    No significant changeCycle cancellation
    Study

    n: not reported in source

    Comparator
    OI-IUI protocol without cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those in the cetrorelix arm showed a significantly reduced rate of PL and no change in clinical pregnancy or cycle cancellation rate,
    1 context sentence
    Summary · context
    Attempting to compare the rates of premature luteinization (PL), clinical pregnancy, and cycle cancellation in ovulation induction-intrauterine insemination (OI-IUI) cycles with and without the GnRH antagonist, cetrorelix, a randomized-controlled trial was undertaken in which patients were randomize…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.